 The Federal Trade Commission plans to sue the three largest pharmacy benefit managers over the price of several medications, including insulin. This is the FTC's most aggressive action on drug companies, which is a big turnaround from past policies that have been pretty hands-off. The White House has made lowering insulin prices a main focus. Congress already capped insulin prices for Medicare patients at $35. The FTC's lawsuit could be filed later this month.